INTRODUCTION
============

The AT-rich interactive domain 1A (SWI-like) gene (*ARID1A*) encodes BAF250A which is a member of the SWI/SNF adenosine triphosphate-dependent chromatin-remodeling complexes \[[@B1]\]. The SWI/SNF complex has been shown to play an essential role in controlling gene expression \[[@B2]\] and is also involved in tissue development and cellular differentiation \[[@B3],[@B4]\]. Inactivation of several components of this complex had been found to be associated with certain type of cancer. For example, INI1 (also called BAF47, SNF5) is frequently deleted in rhabdoid tumor and atypical teratoid/rhabdoid tumor of the central nervous system \[[@B5]-[@B7]\]. The ATPase subunit genes including BRG1 and BRM have been found to be lost in about 15%-20% of primary non-small cell lung cancers, and loss of *BRG1/BRM* are associated with poor prognosis \[[@B8],[@B9]\]. *ARID1A*, containing a DNA-binding motif (ARID), is located at Ch1p36.11, a region frequently deleted in human cancers \[[@B10]\]. Functional genomics analysis demonstrates homozygous deletion involving the 5\' end of *ARID1A* in a lung adenocarcinoma cell line, suggesting *ARID1A* has a tumor suppressor role \[[@B11]\]. Deficient expression of *ARID1A* had been found in carcinomas from several organs, and most frequent in carcinomas of the breast and kidney \[[@B12]\]. Recently, using whole exome sequencing and transcriptome sequencing, mutation of *ARID1A* was found in 43%-57% of ovarian clear cell carcinomas \[[@B13],[@B14]\] and 30% of ovarian endometrioid carcinomas \[[@B14]\].

MUTATION PROFILES OF *ARID1A* IN MALIGNANCIES
=============================================

Following the discovery of inactivating mutations of *ARID1A* in gynecologic tumors, mutations of *ARID1A* had been found in many human malignancies based on next generation sequencing. These mutation frequency varies among tumor types: 3.2%-3.5% in breast carcinoma \[[@B15],[@B16]\], 9.1%-15% in esophageal adenocarcinoma \[[@B17],[@B18]\], 8%-27% in gastric carcinoma \[[@B16],[@B19],[@B20]\], 8% in pancreatic carcinoma \[[@B16],[@B21]\], 10%-13% in hepatocellular carcinoma \[[@B22],[@B23]\], 13% in transitional cell carcinoma of the bladder \[[@B20]\], 8% in prostate carcinoma \[[@B16]\], 6% in neuroblastoma \[[@B24]\], 2% in medulloblastoma \[[@B16]\], and 17% in Burkitt lymphoma \[[@B25]\].

Study on the characteristics of gastric carcinomas harboring *ARID1A* mutations revealed the higher frequency of microsatellite instability (MSI) and Epstein-Barr virus infection and the less likelihood of having mutation of *TP53* \[[@B20]\]. Besides, *ARID1A*-mutated gastric carcinomas with MSI usually have indels involving the mononucleotide repeats of C or G, especially one single G tract located in exon 20. Zang et al. \[[@B19]\] also reported a significant association of *PIK3CA* mutation and MSI with *ARID1A* mutation in gastric carcinomas.

BIOLOGY OF ARID1A AS A TUMOR SUPPRESSOR
=======================================

The majority of *ARID1A* mutations are frame shift or nonsense mutations, suggesting that *ARID1A* is a tumor suppressor. It has been reported that restoring the expression of wild-type *ARID1A* in ovarian cancer cells harboring deleterious *ARID1A* genes was sufficient to suppress cellular proliferation and tumor growth in mice \[[@B26]\]. Conversely, silencing *ARID1A* expression in non-transformed epithelial cells enhanced cellular proliferation and tumorigenicity in a mouse tumor xenograft model \[[@B26]\]. Similarly, in an esophageal cancer model, knockdown of *ARID1A* in cell lines enhanced cellular proliferation, and re-expression of *ARID1A* in *ARID1A*-deleted cell lines significantly suppressed proliferation \[[@B18]\]. At the molecular level, *ARID1A/BRG1* complex has been shown to directly interact and collaborate with p53 to transcriptionally regulate several downstream effectors including those encoded by *CDKN1A* (p21) and *SMAD3* \[[@B26]\]. Using biochemistry approaches, investigators have found that ARID1A acts as a nucleocytoplasmic protein whose stability depends on its subcellular localization \[[@B27]\]. Nuclear ARID1A is unstable as compared to cytoplasmic ARID1A because the protein is rapidly degraded by the ubiquitin-proteasome system in the nucleus. In-frame deletions that disrupt the consensus nuclear export signal are associated with a reduced steady-state protein level of ARID1A due to its retention in the nuclei and subsequent degradation \[[@B27]\]. These findings delineate the basic biological mechanism regulating ARID1A subcellular distribution and protein stability \[[@B27]\]. In summary, recently published studies provided new evidence that ARID1A functions as a tumor suppressor and may participate in both tumor initiation and progression of in human cancer including endometrium-related neoplasms.

ARID1A EXPRESSION AND MUTATION IN GYNECOLOGIC NEOPLASMS
=======================================================

1. Alteration of ARID1A in ovarian tumors
-----------------------------------------

As previously discussed, among human tumors studied so far, gynecologic tumors have the highest frequency of mutation of *ARID1A*, in which ovarian clear cell carcinoma is most frequenty mutated (43%-57%) \[[@B13],[@B14]\]. Mutation of *ARID1A* correlates with loss of protein expression \[[@B14],[@B28]\], since most mutations are frameshift or nonsense mutations, leading to loss of protein expression. Ovarian endometrioid carcinoma has a mutation rate of 30%, while none of the high-grade serous carcinomas and mucinous caricnomas has mutation of *ARID1A* \[[@B14],[@B29]\]. Ovarian clear cell carcinoma can be devided into cystic and adenofibromatous type based on the growth pattern of the tumor \[[@B30]\]. Cystic type clear cell carcinomas are more frequently associated with endometriosis, present at early stage, and tend to have favorable outcome. Yamamoto et al. \[[@B31]\] compared endometriosis and adenofibroma-associated ovarian clear cell carcinomas, and found that loss of ARID1A was more frequent in endometriosis-associated carcinomas than in adenofibroma-assocaited carcinomas (61% vs. 43%), although the difference was not statistically significant. The endometriotic cyst epithelium of non-atypical endometriosis, atypical endometriosis, benign and borderline clear cell adenofibroma adjacent to carcinomas with deficient ARID1A expression, showed ARID1A loss in 86% to 100% of the cases, reflecting that inactivation of ARID1A occurs in the early stages of tumor development. In contrast to the endometriotic lesions adjacent to carcinomas, endometriosis distant from ARID1A-deficient carcinomas and solitary endometrioses had retained ARID1A expression. Similarly, Ahyan et al. \[[@B32]\] studied the expression of ARID1A in ovarian clear cell and endometrioid carcinomas arising from endometrioma. Concurrent loss of ARID1A was found in carcinomas and the contiguous endometriotic epithelium in all tumors with deficient ARID1A expression, while the cystic epithelium distant from the tumors had retained ARID1A expression. *PIK3CA*, another gene frequently mutated in ovarian clear cell carcinoma (33%-46%) \[[@B33],[@B34]\], was also found to be frequently mutated in the endometriotic epithelium adjacent to clear cell carcinomas \[[@B34]\]. The same authors further found that mutation of *PIK3CA* frequently co-exists with loss of ARID1A expression in ovarian clear cell caricnoma \[[@B31],[@B35]\].

In borderline ovarian tumors, loss of ARID1A immunoreactivity was found in 33% of endocervical-type mucinous (seromucinous) borderline tumors, 1 (13%) of borderline endometrioid tumor, and none of the borderline serous tumor and gastrointestinal-type borderline mucinous tumors \[[@B36]\]. Endocerivcal-type mucinous borderline tumors, although also named seromucinous tumors due to endocervical and serous morphology, frequently contain features of endometrioid tumors, including ciliated cells, endometrial-type cells with abundant eosinophilic cytoplasm, and hobnail-shaped cells. In conjunction with the frequent association of endometriosis and mutation and/or loss of *ARID1A*, they are more closely related to endometrial-type proliferative lesions such as ovarian clear cell carcinoma and endometrioid carcinoma. Collectively, these tumors are called \"endometriosis-related ovarian neoplasms\" \[[@B37]\]. How endometriosis leads to the development of these neoplasms is unclear. It is postulated that repeated epithelial damage and repair in an endometriotic microenvironment rich in iron-induced free radicals contribute to the neoplastic transformation of the endometriotic epithelial cells \[[@B38],[@B39]\].

2. Alteration of *ARID1A* in uterine carcinomas
-----------------------------------------------

Similar to the ovarian tumors, endometrial endometrioid carcinomas have high frequency of alteration of *ARID1A*. Mutation was found in 40% of low-grade endometrioid carcinoma and loss of expression was founded in 26%-29% of low-grade endometrioid carcinoma and up to 39% of high-grade endometrioid carcinoma \[[@B29],[@B40]\]. Interesting, *ARID1A* mutations frequently co-ocurr with mutations of *PTEN* and *PIK3CA*, as well as overall PIK3CA pathway aberration. Furthermore, PI3K pathway activity is regulated by ARID1A through phohsphorylation of AKT \[[@B41]\]. In the dualistic pathogenetic pathway of endometrial carcinoma, endometrioid carcinoma belongs to type I carcinoma which shows frequent mutations of *KRAS*, *PTEN*, *PIK3CA*, *CTNNB1*, and microsatellite instability \[[@B42]\]. Alteration of PI3K pathway was found in \>80% of endometrial endometrioid carcinoma \[[@B43]\]. Regulation of PI3K pathway by ARID1A further suggests that ARID1A plays an important role in the pathogenesis of type I endometrial carcinomas. McConechy et al. \[[@B44]\] used a nine-gene mutation profile to subclassify endometrial carcinomas. The nine genes included *ARID1A*, *PPP2R1A*, *PTEN*, *PIK3CA*, *KRAS*, *CTNNB1*, *TP53*, *BRAF*, and *PPP2R5C*. By target enrichment sequencing, each endometrial carcioma subtype exhibits a distinct mutation profile. Mutation of *ARID1A* was detected in 46.7% low-grade endometrioid carcinoma, 60% high-grade endometrioid carcinoma, 10.8% serous carcinoma, and 23.8% carcinosarcoma. The frequency of mutation of *ARID1A* is significantly different between endometrioid carcinoma and serous carcinoma. Interetingly, the molecular profile of carcinosarcomas showed either endometrioid type (mutation of *PTEN* and *ARID1A*) or serous type (mutation of *TP53* and *PPP2R1A*). The relationship between loss of ARID1A and MSI in endometrial endometrioid carcinoma has been recently demonstrated \[[@B45],[@B46]\]. In one report \[[@B45]\], and loss of ARID1A is significantly more frequent in sporadic MSI than in Lynch syndrome. The authors concluded that *ARID1A* is a causative gene instead of a target gene of MSI by the role in epigenetic silencing of the *MLH1* gene in endometrial carcinoma. In another report \[[@B46]\], loss of ARID1A is associated with mismatch repair deficiency. *In vitro* functional study showed that *ARID1A* controls tumor growth by collaboration with p53 and regulates p53 downstream targets \[[@B26]\]. By examining tumor samples, mutations of *ARID1A* and *TP53* were mututally exclusive in ovarian clear cell carcinomas, and uterine carcinomas \[[@B46]\] endometrial endometrioid carcinomas. Immunohistochemically, loss of ARID1A and mutant-like p53 expression was found to be nearly mutually exclusive in endometrial carcinomas \[[@B45],[@B46]\].

Besides genomic study, immunohistochemistry provided an opportunity for the evaluation of heterogeneity in endometroid carcinomas. Clonal loss of ARID1A immunoreactivity in a discrete tumor area against a background of ARID1A positive tumor cells was observed in some tumors with *ARID1A* mutation, suggesting mutations arising from subclones within these tumors. On the other hand, tumors with wild-type *ARID1A* did not exhibit any pattern of clonal loss \[[@B29]\]. This phenomenon was further elucidated in a recent study, showing clonal loss of ARID1A immunoreactivity in 16% complex atypical hyperplasia, 24% of low-grade endometrioid carcinoma, and 10% of high-grade endometrioid carcinma, while complete loss of ARID1A was found in 0% of complex atypical hyperplasia, 25% of low-grade endometrioid carcinoma, and 43% of high-grade endometrioid carcinoma ([Fig. 1](#F1){ref-type="fig"}) \[[@B47]\]. Thus, ARID1A plays important role not only in tumor initiation, but also in tumor progression.

3. Alteration of ARID1A and tumor behavior in gynecologic cancers
-----------------------------------------------------------------

Several studies had investigated the behavior of tumors showing ARID1A alterations. Maeda el al. \[[@B28]\] found no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival in 149 ovarian clear cell carcinomas. Similarly, Yamamoto et al. \[[@B34]\] also found no correlation of ARID1A immunoreactivity with any clinicopathological parameters except the higher association with adjacent endometriosis in 90 ovarian clear cell carcinomas. Lowery et al. \[[@B48]\] examined 212 ovarian clear cell and endometrioid carcinomas and found no relationship between loss of ARID1A and stage, grade, survival or epidemiological variables. In endometrial cancers, Fadare et al. \[[@B49]\] showed that loss of ARID1A was found in 22.7% of endometrial clear cell carcinomas, and cases with loss of ARID1A were significantly high in late stages, but later on they found no association with reduced overall or progression-free survival \[[@B50]\]. On the other hand, loss of ARID1A was reported to be associated with reduced progression-free survival and chemoresistance in ovarian clear cell carcinoma \[[@B51]\] and deep myometrial invasion in endometrial carcinoma \[[@B52]\]. The differences of the impact on prognosis may be due to different antibodies used, sample size variation, and probably other co-factors that affect the behavior of the tumors.

CONCLUSION
==========

Disorganized chromatin structure is known to be associated with the appearance of various abnormal phenotypes, including cancer \[[@B53],[@B54]\]. *ARID1A*, a gene participated in chromatin remodeling, is an emerging tumor suppressor gene. Accumulating evidence has reported somatic inactivating mutations of *ARID1A* and loss of its expression in many types of human cancers, especially in endometrium-derived tumors, including ovarian clear cell carcinomas, ovarian endometrioid carcinomas and uterine endometrioid carcinomas. The high prevalence of somatic mutations in those ovarian and endometrial cancers indicates a pivotal role of ARID1A in their development. Understanding the roles of ARID1A in the pathogenesis of endometrium-derived tumors is fundamental for future translational studies aimed at designing new diagnostic tests for early detection and identifying critical molecular targets for new therapeutic interventions.
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